• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估法国 3 年预后评分在英国囊性纤维化人群中的有效性和适用性 - 一项全国队列研究。

Assessing the validity and applicability of the French 3-year prognostic score in the UK cystic fibrosis population - a national cohort study.

机构信息

Adult CF Unit, Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.

Liverpool Heart and Chest Hospital NHS Trust, Liverpool, UK.

出版信息

Transpl Int. 2021 Mar;34(3):436-444. doi: 10.1111/tri.13805. Epub 2021 Jan 24.

DOI:10.1111/tri.13805
PMID:33486768
Abstract

Models that predict outcomes, aid prognostication and inform the assessment of urgency for lung transplantation (LT) in CF are in demand. A prognostic score derived from the French adult CF registry to predict death or LT over 3-year follow-up was described in 2017 and validated using Canadian CF registry data. We assessed its performance in the UK CF population. The French prognostic score was applied to untransplanted adults with CF. The index year (2014) and outcomes (Death or LT) were evaluated to 2017. Receiver operator characteristics plots and area under curve (AUC) was computed. 4407 adults with CF met the inclusion criteria. After 3 years, 7.1% (P < 0.001) were dead or had received LT compared to the French (12.8%) and Canadian (9.4%) cohorts. The French score deemed 592 (26.2%) 'High-risk' - death/LT occurred in 189/592 (30.2%), less than previously reported in France and Canada (P < 0.0001). The discriminatory power of the French score was lower (AUC 0.830) than reported. Recalibration yielded only marginal improvement in model performance (AUC 0.833). The French prognostic score does not perform as well in the UK as reported elsewhere. Bespoke UK scores are needed to aid prognostication and inform LT decision-making.

摘要

预测结局、辅助预后判断并为肺移植(LT)的紧迫性评估提供信息的模型在 CF 中需求量很大。2017 年描述了一种源自法国成人 CF 登记处的预后评分,用于预测 3 年随访期间的死亡或 LT,并使用加拿大 CF 登记处的数据进行了验证。我们评估了其在英国 CF 人群中的表现。该法国预后评分应用于未接受移植的 CF 成年患者。评估了索引年(2014 年)和结局(死亡或 LT)至 2017 年。计算了接收者操作特征图和曲线下面积(AUC)。4407 名 CF 成年患者符合纳入标准。3 年后,7.1%(P<0.001)死亡或接受 LT,而法国(12.8%)和加拿大(9.4%)队列的这一比例分别为 7.1%和 9.4%。法国评分认为 592 名(26.2%)患者为“高危”-592 名中有 189 名(30.2%)发生死亡/LT,这一比例低于法国和加拿大的先前报告(P<0.0001)。法国评分的判别能力较低(AUC 0.830)。重新校准仅略微改善了模型性能(AUC 0.833)。法国预后评分在英国的表现不如其他地方报道的那样好。需要定制英国评分来辅助预后判断并为 LT 决策提供信息。

相似文献

1
Assessing the validity and applicability of the French 3-year prognostic score in the UK cystic fibrosis population - a national cohort study.评估法国 3 年预后评分在英国囊性纤维化人群中的有效性和适用性 - 一项全国队列研究。
Transpl Int. 2021 Mar;34(3):436-444. doi: 10.1111/tri.13805. Epub 2021 Jan 24.
2
Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry.使用加拿大囊性纤维化注册中心验证法国 3 年预后评分。
J Cyst Fibros. 2019 May;18(3):396-398. doi: 10.1016/j.jcf.2018.10.014. Epub 2018 Nov 3.
3
A 3-year prognostic score for adults with cystic fibrosis.成人囊性纤维化 3 年预后评分。
J Cyst Fibros. 2017 Nov;16(6):702-708. doi: 10.1016/j.jcf.2017.03.004. Epub 2017 Mar 18.
4
Validation of the French 3-year prognostic score for death or lung transplant in the United States cystic fibrosis population.验证法国 3 年预后评分在美国囊性纤维化人群中对死亡或肺移植的预测价值。
J Cyst Fibros. 2022 May;21(3):471-474. doi: 10.1016/j.jcf.2021.08.008. Epub 2021 Aug 28.
5
Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis.囊性纤维化患者 1 年和 2 年死亡率预测模型的建立与外部验证。
Eur Respir J. 2019 Sep 5;54(3). doi: 10.1183/13993003.00224-2019. Print 2019 Sep.
6
Health care resource utilization preceding death or lung transplantation in people with cystic fibrosis: HCRU before transplant or death in cystic fibrosis.囊性纤维化患者死亡或肺移植前的医疗资源利用:囊性纤维化患者移植或死亡前的医疗资源利用情况
J Cyst Fibros. 2024 Sep;23(5):903-909. doi: 10.1016/j.jcf.2024.03.001. Epub 2024 Mar 12.
7
Extra-respiratory comorbidities and transplantation in the French cystic fibrosis registry.法国囊性纤维化注册研究中的肺部外合并症与移植。
Expert Rev Respir Med. 2019 Aug;13(8):799-802. doi: 10.1080/17476348.2019.1638768. Epub 2019 Jul 3.
8
Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada.法国高急诊肺移植计划对囊性纤维化的影响:与加拿大比较得出的见解。
Eur Respir J. 2022 Jan 27;59(1). doi: 10.1183/13993003.00014-2021. Print 2022 Jan.
9
MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION.肺移植后成年囊性纤维化患者的葡萄糖代谢明显延迟胰岛素分泌和高比例未检出的显性糖尿病。
Endocr Pract. 2019 Mar;25(3):254-262. doi: 10.4158/EP-2018-0461.
10
Glucose tolerance in Canadian and French cystic fibrosis adult patients.加拿大和法国囊性纤维化成年患者的葡萄糖耐量。
Sci Rep. 2019 Mar 18;9(1):4763. doi: 10.1038/s41598-019-40592-9.

引用本文的文献

1
Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV ≤ 50% Predicted.开发并内部验证了一个预测模型,用于预测囊性纤维化且 FEV1 预计值≤50%的患者在 2 年内死亡或需要肺移植的概率。
Chest. 2022 Oct;162(4):757-767. doi: 10.1016/j.chest.2022.05.021. Epub 2022 May 26.